Cord Blood Registry (CBR) is the world’s largest newborn stem cell company. Founded in 1992, CBR is
entrusted by parents with storing samples from more than 600,000 children. CBR is dedicated to advancing the
clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish
FDA-regulated clinical trials for conditions that have no cure today.
CBR has helped more than 450+ families use their cord blood stem cells for established and experimental
medical treatments, more than any other family cord blood bank. CBR’s goal is to expand the potential
scope of newborn stem cell therapies that may be available to patients and their families.
Cord Blood Registry is headquartered in South San Francisco, California. CBR’s owned 80,000 square
foot laboratory is located in Tucson, Arizona.
Cord Blood Registry is a registered trademark of CBR Systems, Inc.
History of Quality
CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA
CBR has the longest history of accreditation with the AABB (formerly known as the American Association of
Blood Banks) and the company’s quality standards have been recognized through ISO 9001:2008
certification — the global business standard for quality.
A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem
cells to improve lives today and their potential to revolutionize treatment for many conditions in the
CBR is the first family newborn stem cell bank to partner with leading research institutions to establish FDA-regulated clinical trials
exploring the potential regenerative ability of stem cells to help treat conditions that have no cure today,
including: acquired hearing loss, autism, cerebral palsy, and pediatric stroke. In fact, 73% of the stem cell
units released by CBR have been used for experimental regenerative therapies – more than any other
family cord blood bank in the world.
CBR created the world’s only collection device designed specifically for cord blood stem cells.
Collection Kit contains everything the healthcare provider needs to help maximize the cord blood
CBR developed a crush-resistant, temperature protected, and electronically tracked kit that actively
transforms into a cube to encase the blood and/or tissue collection, helping to ensure that it is protected
and delivered safely. On average, the transport
time from the hospital to CBR’s lab is 19 hours. CBR processes cord blood using the AutoXpress® Platform* (AXP®) — a fully
automated, functionally closed stem cell processing technology. CBR has the industry’s highest
published average cell recovery rate of 99%.1-3,8
*AXP and AutoXpress are registered trademarks of ThermoGenesis Corp